We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

116 hedge funds and large institutions have $51.1M invested in Ventyx Biosciences in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less funds holding

Funds holding: 124116 (-8)

14.59% less ownership

Funds ownership: 77%62.42% (-15%)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

36% less call options, than puts

Call options by funds: $39K | Put options by funds: $61K

57% less capital invested

Capital invested by funds: $119M → $51.1M (-$68.2M)

Holders
116
Holders Change
-8
Holders Change %
-6.45%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
15
Increased
39
Reduced
34
Closed
23
Calls
$39K
Puts
$61K
Net Calls
-$22K
Net Calls Change
+$154K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$5.11M -$107K -62,457 -1%
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$4.87M +$4.21M +2,452,797 +138%
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.04M +$8.78K +5,112 +0.1%
TCM
4
Tang Capital Management
California
$3.56M
SCM
5
Sio Capital Management
New York
$2.97M -$2.51M -1,464,142 -36%
VPC
6
Vestal Point Capital
New York
$2.3M
RG
7
Redmile Group
California
$1.81M +$2.48M +1,445,615 +1,164%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.68M +$86K +50,064 +4%
Citadel Advisors
9
Citadel Advisors
Florida
$1.6M -$5.3M -3,088,129 -69%
State Street
10
State Street
Massachusetts
$1.43M +$50.7K +29,540 +2%
IC
11
Ikarian Capital
Texas
$1.4M +$215K +125,000 +11%
MAM
12
Monaco Asset Management
Monaco
$1.3M +$1.54M +894,444 +373%
JP Morgan Chase
13
JP Morgan Chase
New York
$1.2M +$198K +115,552 +12%
Bank of America
14
Bank of America
North Carolina
$1.17M -$5.59M -3,256,793 -76%
Renaissance Technologies
15
Renaissance Technologies
New York
$1.17M +$673K +391,889 +63%
SFM
16
Sphera Funds Management
Israel
$1.16M
AQR Capital Management
17
AQR Capital Management
Connecticut
$1.01M +$1.36M +794,401 +926%
Morgan Stanley
18
Morgan Stanley
New York
$1.01M -$2.81M -1,634,715 -65%
Connor, Clark & Lunn Investment Management (CC&L)
19
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1M +$134 +78 +0%
Goldman Sachs
20
Goldman Sachs
New York
$682K -$1.58M -917,509 -61%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$614K +$753K +438,286 +444%
Walleye Capital
22
Walleye Capital
New York
$580K +$45.4K +26,457 +6%
Northern Trust
23
Northern Trust
Illinois
$552K -$9.16K -5,333 -1%
Charles Schwab
24
Charles Schwab
California
$516K -$69.3K -40,372 -8%
Macquarie Group
25
Macquarie Group
Australia
$495K

VTYX Hedge Fund Activity: Q1 2025 in Review

116 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q1 2025, worth a combined $51.1M — down 57% from $119M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of VTYX and 15 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 39 added.

The largest buyer was Point72 Asset Management, adding an estimated $4.21M. The largest seller was UBS Group, cutting an estimated $5.96M.

  • 116 institutional investors held Ventyx Biosciences (VTYX) as of Q1 2025, down from 124 in Q4 2024.
  • Funds reported $51.1M of Ventyx Biosciences stock for Q1 2025, down 57% quarter-over-quarter.
  • 15 funds opened new Ventyx Biosciences positions in Q1 2025 and 23 closed out, a net change of -8 holders.
  • The largest Ventyx Biosciences buyer in Q1 2025 was Point72 Asset Management, an estimated $4.21M added.
  • The largest Ventyx Biosciences seller in Q1 2025 was UBS Group, an estimated $5.96M sold.

Based on aggregated 13F filings for Q1 2025.